Cargando…

Immune Checkpoint Inhibitor-related Endocrinopathies

Detalles Bibliográficos
Autores principales:	Lu, Difei, Gao, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997801/ https://www.ncbi.nlm.nih.gov/pubmed/35702188 http://dx.doi.org/10.2478/jtim-2022-0009

Ejemplares similares

Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
por: Shalit, Almog, et al.
Publicado: (2023)

SAT443 Prevalence Of Immune Checkpoint Inhibitor-related Endocrinopathies In Patients With Cancers
por: Pittampalli, Shanti, et al.
Publicado: (2023)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

MON-365 Immune Checkpoint Inhibitors: Endocrinopathies and Severe Electrolyte Abnormalities
por: El Mais, Rania, et al.
Publicado: (2019)

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
por: Okura, Naoko, et al.
Publicado: (2020)

Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer
por: Percik, Ruth, et al.
Publicado: (2023)

Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
por: Gunawan, Florence, et al.
Publicado: (2018)

Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival
por: Ornelas, Mariana, et al.
Publicado: (2023)

Incidence and Phenotypes of Endocrinopathies in Association With Immune Checkpoint Inhibitors: The Experience of Integrated Health Network
por: Mehmood, Hassan, et al.
Publicado: (2021)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
por: Tan, Meng H., et al.
Publicado: (2019)

Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies
por: Chen, Hong, et al.
Publicado: (2023)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature
por: Newman, Christine, et al.
Publicado: (2021)

Endocrinopathies in Inborn Errors of Immunity
por: Takasawa, Kei, et al.
Publicado: (2021)

FRI344 Is It Possible To Have Two Endocrinopathies From Checkpoint Inhibitor Therapy At The Same Time?
por: Davis, Adam N, et al.
Publicado: (2023)

SAT-414 A Single Center Retrospective Analysis and Review of Endocrinopathies from Immune Checkpoint Inhibitors Between 2007 and 2017
por: Shariff, Afreen Idris, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System
por: Lu, Difei, et al.
Publicado: (2022)

Immune checkpoint inhibitors win the 2018 Nobel Prize
por: Huang, Pei-Wei, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
por: Rizzo, Alessandro
Publicado: (2022)

Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection
por: Gambichler, Thilo, et al.
Publicado: (2020)

Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research
por: Cheung, Yee-Ming M, et al.
Publicado: (2023)

Endocrinopathies and Male Infertility
por: Sengupta, Pallav, et al.
Publicado: (2021)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

Pediatric endocrinopathies related to COVID-19: an update
por: Memar, Elmira Haji Esmaeli, et al.
Publicado: (2022)

Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
por: Fane, Lauren S., et al.
Publicado: (2022)

Human immunodeficiency virus endocrinopathy
por: Sinha, Uma, et al.
Publicado: (2011)

Endocrinopathies in Survivors of Childhood Neoplasia
por: Barnes, Nicole, et al.
Publicado: (2014)

Imaging of pediatric pituitary endocrinopathies
por: Chaudhary, Vikas, et al.
Publicado: (2012)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Therapy for Orbital and Ocular Adnexal Squamous Cell Carcinomas: International Society of Ocular Oncology President's Lecture, 2022
por: Esmaeli, Bita
Publicado: (2023)

Immune checkpoint molecules: “new” kids on the block of skin photoimmunology
por: Wang, Wei, et al.
Publicado: (2019)

PSUN160 Transfusion Related Endocrinopathies and Thalassemia (TREAT) Study
por: Erkin-Cakmak, Ayca, et al.
Publicado: (2022)

The future of immune checkpoint combinations with tumor-targeted small molecule drugs
por: Sceneay, Jaclyn, et al.
Publicado: (2021)

LBSAT236 A Case of Immune Checkpoint Inhibitor Pembrolizumab Induced Simultaneous Rare Endocrinopathies, Type 1 DM (presenting As DKA) And Grave's Thyrotoxicosis, With Evidence Of Autoimmunity Development.
por: Arora, Gunjan, et al.
Publicado: (2022)

Coexistence of endocrinopathies in children with rheumatic diseases
por: Alhomaidah, Doha, et al.
Publicado: (2016)

Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
por: Chaudry, Abdul, et al.
Publicado: (2020)

Celiac Disease and the Autoimmune Web of Endocrinopathies
por: Sange, Ibrahim, et al.
Publicado: (2020)

Endocrinopathies complicating transfusion-dependent hemoglobinopathy
por: Al-Agha, Abdulmoein E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3m4v7h6bdee3k8r3qhad1hjsn2